TSC2 and breast carcinoma: As TSC1/TSC2 complex is an activator of mTORC2 signaling and a repressor of mTORC1 and Rheb is an activator of mTORC1 signaling, this data suggests that mTORC2 signaling may be more prominent in ERα+ and mTORC1 signaling may be more prevalent in ERα− breast carcinomas.